RNAi, CRISPR, and Gene Editing: Discussions on How To’s and Best Practices @14th Annual World Preclinical Congress June 10-12, 2015 | Westin Boston Waterfront | Boston, MA
Reporter: Aviva Lev-Ari, PhD, RN
2.2.24 RNAi, CRISPR, and Gene Editing: Discussions on How To’s and Best Practices @14th Annual World Preclinical Congress June 10-12, 2015 | Westin Boston Waterfront | Boston, MA, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair
About Synergistic Use of Functional Genomics Technologies
at World Preclinical Congress
Cambridge Healthtech Institute’s inaugural conference on Synergistic Use of Functional Genomics Technologies brings together experts from all areas of drug discovery and clinical research to talk about how and where functional genomics tools, particularly RNAi (RNA Interference) and CRISPR screens, can be best applied to answer the biological questions asked. Scientists and clinicians from pharma/biotech as well as from academic and government labs will share their experiences leveraging the utility of functional genomics for target identification and validation, high-throughput screening, disease modeling and pathway analysis.
For more information on World Preclinical Congress, CLICK HERE.
Suggested Event Package*
June 10-11: Chemical Biology for Target Validation Conference
June 11-12: Synergistic Use of Functional Genomics Technologies Conference
June 11: Dinner Short Course*: How to Best Utilize Organotypic 3D Cell Cultures in Oncology
Part of the 14th Annual World Preclinical Congress
June 10-12, 2015 | Westin Boston Waterfront | Boston, MA
Topics to be Discussed:
How to pick the right tools for RNAi and gene editing
Related Discussion:
Combining RNAi and Genome Editing: New Avenues for Orthogonal Validation of Functional Genomic Profiles
Samuel Hasson, Ph.D., Principal Investigator, Neuroscience, Pfizer Inc.
How to set-up and run genome-scale RNAi and CRISPR screens
Related Discussion:
Building, Using and Maintaining a Functional Genomics Arsenal
Robert Damoiseaux, Ph.D., Scientific Director, Molecular Shared Screening Resource California NanoSystems Institute, University of California, Los Angeles
CRISPR Screening for drug target identification
Related Discussion:
Gene Editing Tools to Study Malaria Parasite Biology
Jacquin C. Niles, M.D., Ph.D., Associate Professor of Biological Engineering, Massachusetts Institute of Technology
Gene editing in stem cells
Related Discussion:
Multiplexed Gene Editing of Human Pluripotent Stem Cells
Krishanu Saha, Ph.D., Assistant Professor, Biomedical Engineering and Bioethics, University of Wisconsin-Madison
Understanding the pitfalls of gene editing
Related Discussion:
KEYNOTE PRESENTATION: Genome Editing-enabled HTS Assays for Chemical Biology and Translational Research
James Inglese, Ph.D., Head Assay Development & Screening Technologies, National Center for Advancing Translational Sciences (NCATS) and Adjunct Investigator National Human Genome Institute (NHGRI)
Dealing with off-target effects
Related Discussion:
CRISPR Tools for Gene Regulation Applications
Lei Stanley Qi, Ph.D., Assistant Professor, Department of Bioengineering, and Department of Chemical and Systems Biology, Stanford University
SOURCE
From: Functional Genomics Technologies <mikem@worldpharmacongress.com>
Date: Tuesday, May 12, 2015 at 1:00 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: RNAi, CRISPR, and Gene Editing: Discussions on How To’s and Best Practices
Leave a Reply